Ignite Creation Date:
2025-12-24 @ 12:13 PM
Ignite Modification Date:
2026-01-29 @ 10:26 AM
Study NCT ID:
NCT03048461
Status:
WITHDRAWN
Last Update Posted:
2021-12-23
First Post:
2017-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['United States']}, 'conditionBrowseModule': {'meshes': [{'id': 'D000505', 'term': 'Alopecia'}], 'ancestors': [{'id': 'D007039', 'term': 'Hypotrichosis'}, {'id': 'D006201', 'term': 'Hair Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D020763', 'term': 'Pathological Conditions, Anatomical'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 0}}, 'statusModule': {'whyStopped': 'Did not want to enroll and proceed with this study concept.', 'overallStatus': 'WITHDRAWN', 'startDateStruct': {'date': '2019-06', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-12', 'completionDateStruct': {'date': '2020-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-12-22', 'studyFirstSubmitDate': '2017-02-07', 'studyFirstSubmitQcDate': '2017-02-07', 'lastUpdatePostDateStruct': {'date': '2021-12-23', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-02-09', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2020-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Clinical change of androgenetic alopecia, as determined by scoring photographs', 'timeFrame': 'Baseline to 6 months'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['Androgenetic Alopecia']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the effect of autologous platelet-rich plasma (PRP) in the treatment of androgenetic alopecia.\n\nThis is a randomized clinical trial to evaluate the effect of autologous platelet rich plasma in subjects with moderate androgenetic alopecia. Approximately 30 subjects will be randomized into the study. The study is designed as an 18-month study consisting of 2 phases. This study was a pilot study designed to determine feasibility of this procedure.\n\nSubjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Males or females ≥ 18 years old and ≤55 years old\n2. Subjects are in good health as judged by the investigator.\n3. Diagnosed with by a dermatologist with moderate androgenetic alopecia.\n4. Subject is seeking treatment for androgenetic alopecia.\n5. Subject has never previously used finasteride or minoxidil or has consistently used finasteride or minoxidil for at least 1 year.\n6. Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator.\n\nExclusion Criteria:\n\n1. Other than androgenetic alopecia, evidence of another skin condition affecting the treatment area that would interfere with clinical assessments.\n2. Subjects who are unwilling to avoid initiating treatment with minoxidil or finasteride for the duration of the study; or in subjects who have been treated with minoxidil or finasteride for at least 1 year, unwilling to avoid changes in the dosing regimen of these medications for the duration of the study.\n3. Willing to refrain from washing hair or using hair product 24 hours before and after treatment visits\n4. History of a clinically significant hematologic disorder as determined by the investigator.\n5. Subjects currently receiving anticoagulant or anti-platelet therapy.\n6. Subjects on daily Aspirin therapy for cardiovascular disease.\n7. Subjects with chronic NSAID use, unable to wean off.\n8. Subject is known to be HIV positive.\n9. History of recurrent facial or labial herpes simplex infection\n10. History of hypertrophic scars or keloids\n11. Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, etc.\n12. Subjects who have any requirement for the use of local or systemic steroids or other immunosuppressive agent\n13. Pregnant or breast feeding\n14. Uncooperative patients or patients with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.\n15. Subjects who are unable to understand the protocol or give informed consent.'}, 'identificationModule': {'nctId': 'NCT03048461', 'briefTitle': 'The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia', 'organization': {'class': 'OTHER', 'fullName': 'Northwestern University'}, 'officialTitle': 'A Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Effect of Autologous Platelet-rich Plasma in Subjects With Androgenetic Alopecia.', 'orgStudyIdInfo': {'id': 'MA04222016'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Platelet Rich Plasma', 'description': 'Participants will receive intradermal injections autologous PRP to an area (100cm2) of alopecia on the scalp.Two treatments will be performed 3 months apart', 'interventionNames': ['Device: Platelet Rich Plasma Prep System']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo (sterile saline)', 'description': 'Participants will receive intradermal injections of sterile normal saline to an area (100cm2) of alopecia on the scalp. Two treatments will be performed 3 months apart', 'interventionNames': ['Device: Platelet Rich Plasma Prep System', 'Drug: Placebo']}], 'interventions': [{'name': 'Platelet Rich Plasma Prep System', 'type': 'DEVICE', 'description': 'intradermal injections of platelet rich plasma to an area of alopecia', 'armGroupLabels': ['Placebo (sterile saline)', 'Platelet Rich Plasma']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'intradermal injections to an area of alopecia', 'armGroupLabels': ['Placebo (sterile saline)']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Murad Alam, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Northwestern University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Northwestern University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'MD', 'investigatorFullName': 'Murad Alam', 'investigatorAffiliation': 'Northwestern University'}}}}